Exclusion Criteria

Ophthalmic (in either eye):

• Clinically significant ocular disease as deemed by the Investigator that might interfere with the study
• Unwilling or unable to discontinue use of contact lenses at screening until study completion
• Unwilling or unable to suspend use of topical medication at screening until study completion
• Ocular trauma, ocular surgery or non-refractive laser treatment within the 6 months prior to screening
• Use of any topical prescription or over-the-counter (OTC) ophthalmic medications of any kind within 7 days of screening
• Recent or current evidence of ocular infection or inflammation in either eye
• History of diabetic retinopathy or diabetic macular edema
• Closed or very narrow angles that in the Investigator's opinion are potentially occludable if the subject's pupil is dilated
• History of any traumatic (surgical or nonsurgical) or non-traumatic condition affecting the pupil or iris
• Known allergy or contraindication to any component of the mydriatic agents or the vehicle formulation
• History of cauterization of the punctum or punctal plug (silicone or collagen) insertion or removal

Systemic:

• Known hypersensitivity or contraindication to α- and/or β adrenoceptor antagonists.
• Clinically significant systemic disease that might interfere with the study
• Initiation of treatment with or any changes to the current dosage, drug or regimen of any systemic adrenergic or cholinergic drugs within 7 days prior to screening, or during the study
• Participation in any investigational study within 30 days prior to screening
• Females of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control
• Resting HR outside the normal range (50-110 beats per minute)
• Hypertension with resting diastolic BP > 105 mmHg or systolic BP > 160 mmHg